Lv11
56 积分 2026-04-17 加入
Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C
6小时前
待确认
Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes
1个月前
已完结
Covalent inhibitors of human cytochrome P450 3A4: research advances and future perspectives
2个月前
已完结
Synthetic Approaches to the New Drugs Approved During 2024
3个月前
已完结
Recent advances in the design of small molecular drugs with acrylamides covalent warheads
4个月前
已完结
Discovery of a High-Potency Balanced GLP-1/GIP Dual Agonist by Molecular Dynamics Evolution
4个月前
已完结
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
5个月前
已完结
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
5个月前
已完结
皖公网安备34019202002308
